Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone

NCT04710641 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma
Hepatitis B
Hepatitis C

Interventions

DRUG: MTL-CEBPA
DRUG: Sorafenib

Sponsor

Mina Alpha Limited